Ramucirumab/Erlotinib Combo Improves PFS in Frontline EGFR+ NSCLC - OncLive

Ramucirumab/Erlotinib Combo Improves PFS in Frontline EGFR+ NSCLC  OncLive

The combination of ramucirumab and erlotinib significantly improved progression-free survival compared with placebo and erlotinib as a frontline treatment for ...



Comments

Popular posts from this blog

A Review of the Etiology and Epidemiology of Bladder Cancer: All ...

Oncology: The disease, dynamics & challenges of market research

Respirology | APSR Respiratory Medicine Journal